Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder
- 7 September 2012
- journal article
- editorial
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 13 (15) , 2207-2213
Abstract
Introduction: Guanfacine extended release (GXR) is an alpha 1A noradrenergic agonist that has been approved by the FDA for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) as a monotherapy, and as an adjunctive therapy to stimulants for the treatment of ADHD in children and adolescents age 6 – 17. Areas covered: PubMed, the Ovid Medline database, and the PsycInfo database were searched using the term ‘guanfacine'. Results were then limited to criteria such as English and human, from 1990 through December 2011. The resulting yield from the comprehensive literature search was 4391 articles. The titles and abstracts of all articles were reviewed. Studies were selected for full-text review based upon their place in the hierarchy of evidence (e.g., randomized controlled trials), relevance and quality of individual studies, and generalizability to clinical practice. The search was augmented by further search of article reference lists. A total of 15 articles were selected for full-text examination. Expert opinion: Due to the absence of positive evidence for the efficacy of GXR for monotherapy in adolescents, clinicians should be guarded in the use of GXR for monotherapy in adolescents with ADHD. The use of GXR has considerable promise as an adjunct to stimulants for other behavioral conditions associated with ADHD.Keywords
This publication has 37 references indexed in Scilit:
- Adult attention deficit hyperactivity disorder is associated with migraine headachesEuropean Archives of Psychiatry and Clinical Neuroscience, 2011
- Migraine and psychiatric comorbidity: a review of clinical findingsThe Journal of Headache and Pain, 2011
- The Academic Experience of Male High School Students with ADHDJournal of Abnormal Child Psychology, 2010
- The Delinquency Outcomes of Boys with ADHD with and Without ComorbidityJournal of Abnormal Child Psychology, 2010
- Attention-Deficit Hyperactivity DisorderDrugs, 2010
- The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite StudyJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Placebo-Controlled TrialJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity DisorderPediatrics, 2008
- Attention‐Deficit/Hyperactivity Disorder Risk for Heavy Drinking and Alcohol Use Disorder Is Age SpecificAlcohol, Clinical and Experimental Research, 2007
- GuanfacineDrugs, 1986